LYEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Lyell Immunopharma Inc (LYEL) is not a strong buy for a beginner, long-term investor at this moment. Despite a recent analyst upgrade and positive sentiment around its colorectal cancer treatment, the company's financial performance is weak, insiders are selling heavily, and there are no strong trading signals or significant positive catalysts to justify immediate entry. Holding off for more favorable conditions or improved financial performance is recommended.
The MACD is slightly positive, indicating a mild upward trend, but RSI is neutral at 45.27, showing no clear momentum. Moving averages are converging, suggesting indecision in price direction. Key support is at 21.121, and resistance is at 26.377, with the current pre-market price of 22.38 sitting closer to support.
H.C. Wainwright upgraded the stock to Buy with a significant price target increase from $20 to $45, citing strong data for its colorectal cancer treatment and positive expert feedback.
Insiders are selling heavily, with a 256.27% increase in selling activity over the past month. The company's financials are deteriorating, with revenue down 55.88% YoY and EPS dropping by 38.79%. No recent news or Congress trading data to support a bullish case.
In Q3 2025, revenue dropped significantly by 55.88% YoY to $15,000. Net income fell by 12.87% YoY to -$38.85M, and EPS declined by 38.79% YoY to -2.13. Gross margin remained flat at 100%. Overall, the financials indicate poor performance and lack of growth.
H.C. Wainwright upgraded the stock to Buy from Neutral with a price target of $45, up from $20, citing increased conviction in the company's colorectal cancer treatment data and its leadership in the CD19/CD20 CAR-T space.
